In this episode, we are joined by Dr. Tom Beer, Chief Medical Officer and Vice President, Multi-Cancer Early Detection at Exact Sciences, to discuss multi-cancer early detection (MCED) testing and how ...

We have a real-world evidence registry called Falcon, where we're enrolling up to 25,000 individuals who receive annual Cancerguard testing over three years. Our modeling studies suggest that if you ...

Imagine a future where some cancers are caught before symptoms appear, before they spread, before lives are disrupted. That’s the potential of multi-cancer early detection (MCED), a transformative ...

Nearly 70 percent of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening.1,2,3 The Cancerguard test can help address the unmet need by complementing existing ...

Galleri is a blood test that aims to detect over 50 types of cancer early. It analyzes cell-free DNA (cfDNA) and methylation patterns to identify potential cancer signals. The test is intended for ...

Cancerguard by Exact Sciences is the first of its kind early detection blood test for multiple kinds of cancer. Exact Sciences is a diagnostic company focusing on early cancer detection. Cancerguard ...

Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American ...

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings from the PATHFINDER study of ...

Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as ...

(RTTNews) - Exact Sciences Corp. (EXAS) announced the U.S. launch of Cancerguard™, its multi-cancer early detection or MCED blood test, now available as a laboratory-developed test or LDT. Cancerguard ...